Jaguar health announces napo therapeutics' submission of orphan drug designation application to the european medicines agency for crofelemer for a severe congenital diarrheal disorder (cdd) condition

Microvillus inclusion disease (mvid) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea san francisco, ca / accesswire / may 25, 2022 / jaguar health (nasdaq:jagx) today announced that napo therapeutics, the italian corporation established by the company in italy in 2021 that focuses on expanding crofelemer access in europe, has submitted an orphan drug designation (odd) application for crofelemer for a rare congenital diarrheal disorder (cdd) condition called microvillus inclusion disease (mvid) to the european medicines agency (ema). the submission is the first step of the process; the review by the ema's committee for orphan medicinal products (comp) will start after the validation of the submission.
JAGX Ratings Summary
JAGX Quant Ranking